2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Great Hall BC
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Artificial Intelligence (AI), Machine Learning, Biological Processes, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

501 Mutations associated with clinical resistance to menin inhibition

Georgina El Hajjar, MD, Wei Ying Jen, BM BCh, FRCPath2, Aziz Farhat, MD, BS3, Baili Zhang, N/A4, Sanam Loghavi, MD5, Keyur P. Patel, MD6, Guillermo Montalban-Bravo, MD7, Alex Bataller, MD, PhD8, Nicholas Short, MD9, Courtney DiNardo, MD, MSCE10, Tapan Kadia I, MD11, Guillermo Garcia-Manero, MD12, Hagop Kantarjian, MD13, Christopher P Mill, PhD14, Warren Fiskus, PhD15, Michael Andreeff, MD, PhD16, David McCall, MD17, Branko Cuglievan, MD18, Naval Daver, MD19, Elias Jabbour, MD20, Dzifa Duose, PhD21, Ghayas C. Issa, MD22
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Menin inhibition is highly effective in KMT2A-rearranged (KMT2Ar), NUP98-rearranged (NUP98r), and NPM1-mutated (NPM1m) acute myeloid leukemia (AML), but response durability in relapsed or refractory (R/R) disease is limited by primary and acquired resistance. Acquired MEN1 mutations (MEN1m) within the inhibitor binding pocket have emerged as a resistance mechanism, although their frequency, timing, and clinical significance remain unclear.

Methods: We evaluated the clinical impact of baseline co-mutations and acquired MEN1m in patients (pts) with relapsed/refractory (R/R) AML treated with menin inhibitor monotherapy. Baseline mutational profiling was performed using a targeted NGS panel of 81 genes recurrently mutated in acute leukemia (sensitivity of 2%, MEN1 not included). Longitudinal MEN1m testing was done by droplet digital PCR (ddPCR) targeting 8 resistance mutations predicted to impair revumenib binding (Perner Nature 2023). Custom primers and probes targeting wild-type and the 8 MEN1m were developed and optimized, with a limit of detection of 0.1% variant allele frequency (VAF) for M327I/C/A/V and T349M, and 0.05% for S160T and G331R/D. We identified 100 pts with R/R AML treated with menin inhibitor monotherapy who underwent baseline NGS (67 revumenib, 16 ziftomenib, 9 bleximenib, 8 enzomenib). Among those, 63 pts had 173 serial samples tested for MEN1m.

Results: The median age was 32 years (range, 0.8–80); 78 pts (78%) had KMT2Ar, 16 (16%) NPM1m, and 6 (6%) NUP98r. The most frequent baseline co-mutations involved WT1 (27%), NRAS (14%), FLT3 (11%; ITD 5%), KRAS(11%), and TP53 (9%).

Median overall survival (OS) was shorter in pts who had received ≥2 prior lines of therapy (hazard ratio [HR] 2.2, 95% CI 1.3–3.9; P=0.005) and in those previously exposed to venetoclax (HR 2.5, 95% CI 1.5–4.4; P=0.001). Among baseline co-mutations, FLT3 [OS: HR 2.4, 95% CI 1.2–4.7, P=0.01; event-free survival (EFS): HR 1.5, 95% CI 0.8–2.9, P=0.2], KRAS (OS: HR 2.5, 95% CI 1.3–4.9, P=0.009; EFS: HR 2.06, 95% CI 1.03–4.1, P=0.04), and TP53 mutations (OS: HR 2.7, 95% CI 1.2–5.8, P=0.01; EFS: HR 1.8, 95% CI 0.8–3.7, P=0.1) were associated with shorter survival. Among 7 pts with repeat genetic characterization at relapse, the founding KMT2Ar, NUP98r or NPM1mt persisted in all, with persistence or emergence of FLT3 mutations in 2 pts, while KRAS/NRAS mutations persisted in 1 pt and emerged in 3 pts.

Acquired MEN1m were detected in 27% (17/64 evaluable pts) during treatment [revumenib: 15/44 (34%), ziftomenib: 1/9 (11%), bleximenib: 2/8 (25%), enzomenib: 0/7 (0%)]. Of note, this panel did not include inhibitor-specific MEN1m like the enzomenib-specific E368 (Cutler EHA 2026), or the ziftomenib-specific V372A (Bourgeois Nat Commun 2026). No MEN1m were detected at baseline. M327I/A was most common (53%), followed by G331D (35%) and T349M (29%). Less frequently M327I/C (12%), G331R (12%), M327V (6%), S160T (0%). Multiple concurrent MEN1m were identified in 5 pts (29%).

The median time from treatment initiation to 1st detectable MEN1m was 1.8 months (95% CI, 0.9-2.8), same as the median time to clinical progression (1.8 months; 95% CI, 0.9-3.5). MEN1m preceded clinical progression in 46% of pts, with a median lead time of 2 months.

Among responders, acquisition of MEN1m was associated with a shorter duration of response (DOR) (median: 2.8 months vs not reached; HR 3.1; P=0.05), although EFS and OS were similar regardless of MEN1m status. M327I/C had higher VAFs (median: 23%; range 12-28), vs M327I/A (median: 0.9%; range 0.2-23), vs G331R/D (median: 0.1%; range 0.1-25), vs T349M (median: 2%; range 0.1-22). M327I/A had the shortest DOR (median: 1.1 vs 28.2 months for all other pts, P=0.04), consistent with preclinical data demonstrating broad disruption of binding by currently available menin inhibitors (Bourgeois Nat Commun 2026). In contrast, other MEN1m may confer less profound impairment of drug binding, and are often subclonal at relapse, suggesting that additional genetic and non-genetic mechanisms contribute to resistance.

Conclusions: Baseline FLT3, KRAS, and TP53 co-mutations are associated with inferior OS following menin inhibitor monotherapy in R/R AML. M327I/A MEN1m confer the greatest adverse impact on response durability, highlighting the need for combination or next generation menin inhibitors. Further elucidation of mechanisms of resistance to menin inhibition beyond acquisition of MEN1m is needed.
Georgina El Hajjar, MD: No relevant conflicts of interest to declare.